Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
27 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
22 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
21 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
12 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 16h05 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
29 juil. 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
31 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
21 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b